



Contents lists available at ScienceDirect

## Medicine in Drug Discovery

journal homepage: <https://www.journals.elsevier.com/medicine-in-drug-discovery>

## Editorial

## Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis



## ARTICLE INFO

## Article history:

Received 30 April 2020

Received in revised form 5 May 2020

Accepted 6 May 2020

Available online 11 May 2020

## Keywords:

viral infection  
respiratory system  
Warburg effect  
Melatonin  
COVID-19

The pathogenesis of a COVID-19 respiratory infection, in a major way, is related to what is referred to as the cytokine storm [cytokine storm syndrome (CSS, hypercytokinemia, etc.)], i.e., it is a **hyper-inflammatory** response. During this response, an explosive production of proinflammatory cytokines such as TNF- $\alpha$  IL-1 $\beta$ , and others occurs, greatly exaggerating the generation of molecule-damaging reactive oxygen species (free radicals) [1]. In severe cases, the cytokine storm is responsible for the most obvious signs of a COVID-19 infection including fever, lung injury which causes cough and shortness of breath (and the long-term complication, lung fibrosis) and in death.

A causative factor related to the **hyper-inflammatory state of immune cells is their ability to dramatically change their metabolism. Similar to cancer cells in many solid tumors**, immune cells such as macrophages/monocytes under inflammatory conditions abandon mitochondrial oxidative phosphorylation for ATP production in favor of cytosolic aerobic glycolysis (also known as the Warburg effect) [2]. **This switch is driven** by the transcription factor HIF-1 $\alpha$  (hypoxia inducible factor-1 $\alpha$ ) and the serine/threonine kinase, mTOR (mammalian target of rapamycin) and other proteins **The change to aerobic glycolysis** allows immune cells to become highly phagocytic, accelerate ATP production, intensify their oxidative burst and to provide the abundant metabolic precursors required for enhanced cellular proliferation and increased synthesis and release of cytokines (Fig. 1).

A number of drugs have been proposed as treatments to prevent or reduce the severity of a COVID-19 infection. One agent that has been suggested to be potentially useful in this regard is the endogenously synthesized molecule, melatonin [3–7]. Melatonin was initially discovered in and thought to be exclusively a product of the vertebrate pineal gland. However, in consideration of the **identification of melatonin in prokaryotic bacteria [8]**, from which mitochondria evolved (the endosymbiotic theory) and the **uncommonly high levels of assayable melatonin in mitochondria [9]**, it was speculated and eventually documented that this indoleamine is

synthesized in this organelle [10]. Given that most cells (a few exceptions) contain mitochondria, it is now believed that melatonin production occurs in most cells in all organisms. **This has also been specifically demonstrated in human lung monocytes/macrophages [11].**

In healthy cells, including macrophages, melatonin synthesis in mitochondria is maintained by the entrance of pyruvate, a glucose metabolite, into the mitochondria where it is metabolized to acetyl-coenzyme A by the enzyme, pyruvate dehydrogenase complex (PDC). Acetyl-coenzyme A feeds the citric acid cycle and supports ATP synthesis, but it is also a required co-factor/substrate for the rate limiting enzyme in melatonin synthesis, arylalkylamine N-acetyltransferase (AANAT) (Fig. 1). Thus, when mitochondria adopt aerobic glycolysis, pyruvate in mitochondria is no longer converted to acetyl-coenzyme A because PDC is inhibited by the enzyme pyruvate dehydrogenase kinase (PDK); **Therefore, as a consequence of a COVID-19 infection the macrophage mitochondria cannot synthesize melatonin [12].**

Because of melatonin's potent antioxidant and anti-inflammatory activities, it would normally reduce the highly proinflammatory cytokine storm and neutralize the generated free radicals thereby preserving cellular integrity and preventing lung damage. In the absence of acetyl-coenzyme A, mitochondrial melatonin is no longer available to combat the inflammatory response or to neutralize the generated reactive oxygen species and the massive damage that occurs in the respiratory tree resulting in the primary signs of COVID-19 disease. Importantly, endogenous melatonin production diminishes markedly with age especially in frail older individuals. This is consistent with the more serious nature of a COVID-19 infection in the elderly.

Aerobic glycolysis is an important feature of highly proinflammatory state since it ensures the necessary high levels of ATP and the abundant supply of biomolecules to ensure synthesis and release of the damaging molecules that constitute the cytokine storm. This increased aerobic glycolysis coupled with the absence of locally-produced melatonin provides the optimal environment (the perfect “cytokine storm”) for the massive tissue damage that occurs in COVID-19 disease.


Given the above information, the use of supplemental melatonin as a treatment to overcome a COVID-19 infection is justified. Exogenously administered melatonin reverses aerobic glycolysis by repressing both HIF-1 $\alpha$  and mTOR thereby disinhibiting PDC activity and allowing acetyl-coenzyme A synthesis which also ensures locally-produced melatonin production [13]. The functionally re-instated mitochondria-generated melatonin in combination with the parenteral melatonin provides a formidable weapon to reduce the cytokine storm as well as its damaging consequences thereby relieving the signs of a COVID-19 infection.

The anti-inflammatory and antioxidant actions of melatonin in protecting the lungs from damage in many experimental models that involve inflammation or oxidative stress (or both) is well documented [14]. Moreover, melatonin has anti-viral actions against viruses other than

**melatonin is also found in plants**

<http://dx.doi.org/10.1016/j.medidd.2020.100044>

2590-0986/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



**Fig. 1.** This figure illustrates the differential glucose metabolism in a healthy macrophage and in a COVID-19-activated macrophage. In a healthy macrophage, pyruvate, a glucose metabolite, enters the mitochondria where it is enzymatically converted to acetyl-coenzyme A by the enzyme pyruvate dehydrogenase complex (PDC). Acetyl-coenzyme A feeds the tricarboxylic acid cycle (TCA) and supports oxidative phosphorylation (OXPHOS). Additionally, acetyl-coenzyme A is an essential co-factor/substrate for the rate limiting enzyme in melatonin synthesis, arylalkylamine N-acetyltransferase (AANAT). This allows for melatonin to be regularly produced in healthy macrophages; melatonin functions intracellularly and is released into the cellular microenvironment, but not into the blood. In COVID-19-activated macrophages, via HIF-1 $\alpha$ , mTOR, etc., the enzyme pyruvate dehydrogenase kinase (PDK) is strongly upregulated and inhibits PDC (red X). Thus, acetyl-coenzyme A is not synthesized and mitochondrial OXPHOS falters with ATP synthesis occurring in the cytosol via aerobic glycolysis (Warburg effect). Similarly, mitochondrial melatonin production is shut down so the cell is deprived of an essential antioxidant, anti-inflammatory agent and of an immune-enhancer so the elevated synthesis of proinflammatory cytokines goes uncontested and the cytokine storm is a result. 5-HT = serotonin; ASMT = acetylserotonin methyltransferase; CoA = coenzyme A; IMM = inner mitochondrial membrane; HIF-1 $\alpha$  = hypoxia inducible factor-1 $\alpha$ ; mTOR = mammalian target of rapamycin; NAS = N-acetylserotonin; OMM = outer mitochondrial membrane; PPP = pentose phosphate pathway.

COVID-19 [15,16]. The collective data, in addition to its **very high safety profile**, indicate that **melatonin would be effective as a treatment for COVID-19 and support the recommendation of the published reports that encourage its use for this purpose [3–7]. Melatonin is inexpensive, non-toxic over a very wide dose range, has a long shelf-life and can be self-administered which is a major advantage** when large numbers of individuals are involved. Thus, the use of melatonin to mitigate the COVID-19 pandemic would be feasible and a socially-responsible measure to attempt.

**Acknowledgments**

Not applicable.

**Conflict of Interest**

The authors declare no conflict of interest.

**Authors' contributions**

All authors participated in discussions related to melatonin and COVID-19. The first draft of the manuscript was written by RJR; the paper was then

reviewed and edited by all co-authors. The final version of the report was read and approved by all co-authors.

**Funding**

The authors received no funding to support this publication.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**References**

[1] Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. 2020;20:124–7.  
 [2] Bar-Or D, Carrick M, Tanner A, Lieser MJ, Rael LT, Brody E. Overcoming the Warburg effect: is it the key to survival in sepsis? J Crit Care. 2018;43:197–201.  
 [3] Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583.

- [4] Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for human coronavirus. *Cell Disc.* 2020;6:14.
- [5] Peschechera E, Veronesi PA. Injectable melatonin: an anticancer and antiviral treatment option. *Melatonin Res.* 2020;3:77–80.
- [6] Tan DX, Hardeland R. Potential utility of melatonin in deadly infectious diseases related to the overreaction of innate immune response and destructive inflammation: focus on COVID-19. *Melatonin Res.* 2020;3:120–43.
- [7] Shneider A, Kudrivtsev A, Vakhrusheva A. Can melatonin reduce the severity of COVID-19 pandemic? *Int J Immunology.* 2020. <https://doi.org/10.1080/08830185.2020.1756284>.
- [8] Manchester LC, Poeggeler B, Alvares FL, Ogden GB, Reiter RJ. Melatonin immunoreactivity in the photosynthetic prokaryote *Rhodospirillum rubrum*: implications for an ancient antioxidant system. *Cell Mol Biol Res.* 1995;41:391–5.
- [9] Venegas C, Garcia JA, Escames G, Ortiz F, Lopez AD, Doerrier C, et al. Extrpineal melatonin: analysis of its subcellular distribution and daily fluctuations. *J Pineal Res.* 2012; 52:217–27.
- [10] Suofu Y, Jean-Alphonse FG, Jia J, Khattar NK, Li J, Baranov SV, et al. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. *Proc Natl Acad Sci U S A.* 2017;114:E7997–8006.
- [11] Muxel JM, Pires-Lapa MA, Morteiro AW, Cecon E, Tamura EK, Flaeten-Winter LM, et al. NF- $\kappa$ B drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N-acetyltransferase (AA-NAT) gene. *PLoS One.* 2012;7(12):e52010.
- [12] Reiter RJ, Sharma R, Ma Q, Rosales-Corral S, Acuna-Castroviejo D, Escames G. Inhibition of mitochondrial pyruvate dehydrogenase kinase: a proposed mechanism by which melatonin causes cancer cells to overcome cytosolic glycolysis, reduce tumor biomass and reverse insensitivity to chemotherapy. *Melatonin Res.* 2019; 2:105–19.
- [13] Acuna-Castroviejo D, Noguiera-Navarro MT, Reiter RJ. Melatonin actions in the heart: more than a hormone. *Melatonin Res.* 2018;1:21–6.
- [14] Colunga Biancatelli RML, Berrill M, Mohammed YH, Marik PE. Melatonin for the treatment of sepsis: the scientific rationale. *J Thorac Dis.* 2020;12(Suppl. 1): S54–65.
- [15] Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this “molecular handyman?”. *Rev Med Virol.* 2012;22:323–38.
- [16] Reiter RJ, Ma Q, Sharma R. Treatment of Ebola and other infectious diseases: melatonin “goes viral.”. *Melatonin Res.* 2020;3:43–57.

Russel J. Reiter

Ramaswamy Sharma

Qiang Ma

*Department of Cell Systems and Anatomy, UT Health San Antonio,*

*San Antonio, TX, United States of America*

*E-mail address: Reiter@uthscsa.edu*

Alberto Dominquez-Rodriguez

*Department of Cardiology, Hospital Universitario de Canarias,*

*Santa Cruz, Tenerife, Spain*

Paul E. Marik

*Division of Pulmonary and Critical Care Medicine, Eastern*

*Virginia Medical School, Norfolk, VA, United States of America*

Pedro Abreu-Gonzalez

*Department of Physiology, Faculty of Medicine,*

*University of La Laguna, Tenerife, Spain*